ACACIA RESEARCH CORP Q3 FY2025 earnings call

Acacia delivered total revenue of $59.4 million in Q3, up 16% sequentially and 155% year-over-year, driven by the third full quarter of Deflecto. Total company adjusted EBITDA was $8 million, Operated segment adjusted EBITDA was $12.6 million, and free cash flow was $7.7 million. Key initiatives include pricing strategies, cost savings, operational efficiencies, and plant consolidations to mitigate tariff pressures. Benchmark's hedging strategy protects cash flow, with over 70% of operated production hedged through 2028. Deflecto made progress with operational initiatives like price increases, reshoring, and cost reductions despite market headwinds. Printronix continued strong performance with attractive hardware and consumable mix. IP segment had $7.4 million in paid-up revenue from settlements and licenses in Q3.

Energy operations generated $14.2 million in revenue for the quarter, with adjusted EBITDA of $6.1 million and free cash flow of $4.3 million. Manufacturing (Deflecto) had revenue of $30.8 million, adjusted EBITDA of $2.6 million, and free cash flow of $2 million. Industrial (Printronix) reported revenue of $6.7 million, adjusted EBITDA of $0.8 million, and free cash flow of $0.7 million. Intellectual Property operations recorded $7.8 million in revenue and $3 million in adjusted EBITDA for the quarter.

Near-term focus on leveraging diverse portfolio and developing targeted pricing strategies and cost savings to mitigate tariff impacts. Aim to build pipeline for organic and inorganic growth across businesses. Confident in continuing momentum through year-end and into next year to generate long-term value for shareholders.

Persistent macroeconomic and geopolitical headwinds impacting businesses. Tariff pressures affecting segments like Deflecto. Uncertainty in biotech market with early-stage companies. Volatility in private equity market with high debt levels and uncertain trade policies.

Q: Anthony Stoss asked about Deflecto's free cash flow use for debt paydown and EBITDA margins A: Spoke about using free cash flow to pay down debt and target low to mid-teens EBITDA margins Q: Brett Reiss inquired about Benchmark's Cherokee properties A: No wells drilled yet, but optimized acreage through acquisitions and swaps Q: Brett Reiss questioned about Printronix's free cash flow seasonality A: Seasonality is a factor Q: Brett Reiss asked about AMO Pharma's carrying value and potential A: Cautiously optimistic, but didn't disclose carrying value Q: Brett Reiss inquired about TP Link systems impact on IP portfolio A: U.S. IP-friendly environment, but TPLink legal process ongoing Q: Todd Selter talked about IP portfolio settlement on Vantiva A: Part of the $7.4 million settlement mentioned Q: Todd Selter questioned IR initiative A: Started reaching out, presenting at conferences, and engaging with investors Q: Shelley Anthony asked about AMO Pharma's advancements and valuation A: Not changed valuation, cautiously optimistic Q: Shelley Anthony inquired about IR outreach A: Started engaging, presenting, and scheduling conferences to tell the story